Pharmaceutical strategy

This page is also available in:

Tuairimí a glacadh on 27/04/2021 - Bureau decision date: 01/12/2020
Reference
INT/926-EESC-2020-5886
Opinion Type
Optional
Referral
COM(2020) 761 final
Official Journal
OJ C 286, 16.7.2021, p. 53
Rapporteur
Martin SCHAFFENRATH
Civil Society Organisations - GR III
Austria
Pharmaceuticals

The EESC:

  • welcomes the fact that the new pharmaceutical strategy demonstrates the intention to promote the competitiveness of the related industry in Europe but also to ensure the provision of safe, high-quality and bearable medicines and to ensure the financial sustainability of Member States' health systems;
  • stresses the challenge that common strategies represent for drug research and development, as well as for pricing;
  • considers it urgent to review the legal framework currently applicable to medicines, to adapt it and to attach stricter conditions regarding their affordability and availability;
  • stresses the essential role of an operating, fair and effective single market, which also encourages, and also rewards, real medical advances that have real added value for health care, while also working to strengthen competition, with a view to ensuring equitable and financially sustainable access to medicines.

For more information please contact the INT Section Secretariat.

Downloads

Download — Tuairim ó CESE: Pharmaceutical strategy
docx
bg
es
cs
da
de
et
el
en
fr
ga
hr
it
lv
lt
hu
mt
nl
pl
pt
ro
sk
sl
fi
sv

Recommended for you